文献速递呼吸道感染呼吸危重症与机械通气

巨噬细胞膜包覆纳米颗粒控制重症细菌性肺炎炎症并提高生存率

Macrophage membrane-coated nanoparticles control pathological inflammation and enhance survival in models of severe bacterial pneumonia.
PubMed 文献 · Am J Respir Crit Care Med · 2026-07-24

该研究评估巨噬细胞膜包覆纳米颗粒(MΦ-NPs)治疗重症细菌性肺炎的潜力。体外实验显示MΦ-NPs具有细胞保护和抗炎活性且不损害中性粒细胞抗菌功能;小鼠铜绿假单胞菌和MRSA肺炎模型中,MΦ-NPs显著提高生存率、降低细菌负荷和促炎细胞因子并保护肺结构。定量蛋白质组学揭示其抑制与不良预后相关的炎症、凝血和纤维化通路。

要点

  • MΦ-NPs在体外具有细胞保护和抗炎活性,且不影响中性粒细胞抗菌功能。
  • 在PA和MRSA肺炎小鼠模型中,MΦ-NPs显著提高生存率并降低细菌负荷。
  • MΦ-NPs抑制炎症、凝血和纤维化通路,是宿主导向治疗策略。

核心结论

  • MΦ-NPs是减轻重症细菌性肺炎有害炎症后遗症的有前景的宿主导向治疗策略。

研究设计与样本

  • 体外使用人肺内皮细胞、上皮细胞及原代中性粒细胞感染模型。
  • 体内使用铜绿假单胞菌(PA)和耐甲氧西林金黄色葡萄球菌(MRSA)肺炎小鼠模型。

主要发现

  • MΦ-NPs在体外表现出强效细胞保护和抗炎活性,且不损害中性粒细胞抗菌功能。
  • 在PA和MRSA肺炎模型中,MΦ-NP治疗显著提高生存率、降低细菌负荷、降低促炎细胞因子并保护肺结构。
  • 定量蛋白质组学显示MΦ-NPs抑制与人类肺炎和ARDS不良预后相关的炎症、凝血和纤维化通路。

临床怎么用

  • MΦ-NPs作为宿主导向疗法,可能用于重症细菌性肺炎辅助治疗以控制过度炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Severe bacterial pneumonia is a leading cause of death worldwide, and mortality rates remain unacceptably high despite appropriate antibiotic treatment. Macrophage membrane-coated nanoparticles (MΦ-NPs) are biomimetic constructs engineered to neutralize bacterial toxins, pathogen-associated molecular patterns, and proinflammatory cytokines. OBJECTIVE: To evaluate the therapeutic potential of MΦ-NPs for the treatment of severe bacterial pneumonia. METHODS: We evaluated the therapeutic potential of MΦ-NPs using in vitro models of infection involving human lung endothelial and epithelial cells, as well as primary human neutrophils, and in vivo murine models of Pseudomonas aeruginosa (PA) and methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. MAIN RESULTS: MΦ-NPs demonstrated potent cytoprotective and anti-inflammatory activity in vitro, without impairing neutrophil antimicrobial function. In both PA and MRSA pneumonia models, MΦ-NP treatment significantly improved survival, reduced bacterial burden, lowered proinflammatory cytokines, and preserved lung architecture. Quantitative proteomics further revealed suppression of inflammatory, coagulation, and fibrotic pathways associated with poor outcomes in human pneumonia and ARDS. CONCLUSIONS: These findings establish MΦ-NPs as a promising host-directed therapeutic strategy for mitigating the deleterious inflammatory sequelae of severe bacterial pneumonia.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Gage H, Hannah SM, Zhou Z, et al. Macrophage membrane-coated nanoparticles control pathological inflammation and enhance survival in models of severe bacterial pneumonia. Am J Respir Crit Care Med. 2026. PMID: 42496581. doi:10.1093/ajrccm/aamag391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。